Surface modifications, such as tumor-targeting ligands, could enhance circulation time and reduce off-target accumulation, while mechanistic studies elucidating CPN elimination pathways and immune interactions will refine their therapeutic utility. This evidence concerns the gene CPN1 and neoplasm.